{"filing":{"accession_number":"0001935979-26-000083","cik":"0001935979","ticker":"BHVN","company_name":"Biohaven Ltd.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-22","primary_document":"bhvn-20261022.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000083/bhvn-20261022.htm"},"events":[{"id":37006,"run_id":34108,"accession_number":"0001935979-26-000083","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Biohaven disclosed that the FDA has accepted its NDA resubmission for Vyglxia (troriluzole) in SCA for review and assigned a Q1 2027 user fee goal date, with an advisory committee meeting planned. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's pipeline progress and approval prospects, but it does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other defined event types. It is clearly operational/strategic in nature.","company_name":"Biohaven Ltd.","ticker":"BHVN","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41578,"accession_number":"0001935979-26-000083","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Biohaven disclosed that the FDA has accepted its NDA resubmission for Vyglxia (troriluzole) in SCA for review and assigned a Q1 2027 user fee goal date, with an advisory committee meeting planned. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's pipeline progress and approval prospects, but it does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other defined event types. It is clearly operational/strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:01:37.072402+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41578,"accession_number":"0001935979-26-000083","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Biohaven disclosed that the FDA has accepted its NDA resubmission for Vyglxia (troriluzole) in SCA for review and assigned a Q1 2027 user fee goal date, with an advisory committee meeting planned. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's pipeline progress and approval prospects, but it does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other defined event types. It is clearly operational/strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:01:37.072402+00:00","company_name":"Biohaven Ltd.","ticker":"BHVN","filing_date":"2026-10-22"}]}